Lou T, Yang R, Fan J, 2024, The Global Burden of Fatty Liver Disease: The Major Impact of China. Hepatobiliary Surg Nutr, 13: 119–123.

Zhou F, Zhou J, Wang W, et al., 2019, Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology, 70: 1119–1133.

Zhou J, Zhou F, Wang W, et al., 2020, Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology, 71: 1851–1864.

Zheng H, Han L, Shi W, et al., 2022, Research Advances in Lotus Leaf as Chinese Dietary Herbal Medicine. The American Journal of Chinese Medicine, 50: 1423–1445.

Pouwels S, Sakran N, Graham Y, et al., 2022, Non-Alcoholic Fatty Liver Disease (NAFLD): A Review of Pathophysiology, Clinical Management and Effects of Weight Loss. BMC Endocr Disord, 22: 63.

Zarghamravanbakhsh P, Frenkel M, Poretsky L, 2021, Metabolic Causes and Consequences of Nonalcoholic Fatty Liver Disease (NAFLD). Metabolism Open, 12: 100149.

Malnick S, Beergabel M, Knobler H, 2003, Non-Alcoholic Fatty Liver: A Common Manifestation of a Metabolic Disorder. QJM, 96: 699–709.

Cariou B, Byrne C, Loomba R, Sanyal A, 2021, Nonalcoholic Fatty Liver Disease as a Metabolic Disease in Humans: A Literature Review. Diabetes Obes Metab, 23: 1069–1083.

Gabbia D, Cannella L, De Martin S, 2021, The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases. Biomedicines, 9: 687.

Ioannou G, 2021, Epidemiology and Risk-Stratification of NAFLD-Associated HCC. Journal of Hepatology, 75: 1476–1484.

Longo M, Paolini E, Meroni M, et al., 2021, Remodeling of Mitochondrial Plasticity: The Key Switch From NAFLD/NASH to HCC. International Journal of Molecular Sciences, 22: 4173.

Marušić M, Paić M, Knobloch M, et al., 2021, NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Canadian Journal of Gastroenterology and Hepatology, 2021: 6613827.

Palma R, Pronio A, Romeo M, et al., 2022, The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications. Journal of Clinical Medicine, 11: 3649.

Sakurai Y, Kubota N, Yamauchi T, et al., 2021, Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences, 22: 4156.

Ramanathan R, Ali A, Ibdah J, 2022, Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 23: 7280.

Ajaz S, McPhail M, Gnudi L, et al., 2021, Mitochondrial Dysfunction as a Mechanistic Biomarker in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD). Mitochondrion, 57: 119–130.

Clare K, Dillon J, Brennan P, 2022, Reactive Oxygen Species and Oxidative Stress in the Pathogenesis of MAFLD. Journal of Clinical and Translational Hepatology, 10: 939.

Vachliotis ID, Polyzos SA, 2023, The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Current Obesity Reports, 12: 191–206.

Potoupni V, Georgiadou M, Chatzigriva E, et al., 2021, Circulating Tumor Necrosis Factor Alpha Levels in Non Alcoholic Fatty Liver Disease: A Systematic Review and a Meta Analysis. Journal of Gastroenterology and Hepatology, 36: 3002–3014.

Xiong J, Chen X, Zhao Z, et al., 2022, A Potential Link Between Plasma Short-Chain Fatty Acids, TNF Alpha Level and Disease Progression in Non-Alcoholic Fatty Liver Disease: A Retrospective Study. Experimental and Therapeutic Medicine, 24: 598.

Park J, Zhao Y, Zhang F, et al., 2023, IL-6/STAT3 Axis Dictates the PNPLA3-Mediated Susceptibility to Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 78: 45–56.

Skuratovskaia D, Komar A, Vulf M, et al., 2021, IL-6 Reduces Mitochondrial Replication, and IL-6 Receptors Reduce Chronic Inflammation in NAFLD and Type 2 Diabetes. International Journal of Molecular Sciences, 22: 1774.

Liang Z, Chen X, Shi J, et al., 2021, Efficacy and Safety of Traditional Chinese Medicines for Non-Alcoholic Fatty Liver Disease: A Systematic Literature Review of Randomized Controlled Trials. Chinese Medicine, 16: 1–38.

Ding X, He X, Tang B, et al., 2024, Integrated Traditional Chinese and Western Medicine in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: Future Directions and Strategies. Chinese Medicine, 19: 21.

An Y, Hao J, Li J, He W, Wang L, Zhang Y, 2021, The Inhibitory Effect of Lotus Leaf Extract on Hyperuricemia and Its Potential Mechanism. Acupuncture and Herbal Medicine, 1: 122–129.

Xu H, Wang L, Yan K, et al., 2021, Nuciferine Inhibited the Differentiation and Lipid Accumulation of 3T3-L1 Preadipocytes by Regulating the Expression of Lipogenic Genes and Adipokines. Front Pharmacol, 12: 632236.

Arab JP, Arrese M, Trauner M, 2018, Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annual Review of Pathology: Mechanisms of Disease, 13: 321–350.

Sanyal AJ, 2005, Mechanisms of Disease: Pathogenesis of Nonalcoholic Fatty Liver Disease. Nature Clinical Practice Gastroenterology & Hepatology, 2: 46–53.

Lonardo A, Nascimbeni F, Ballestri S, et al., 2019, Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology, 70: 1457–1469.

Morán-Costoya A, Proenza AM, Gianotti M, Lladó I, Valle A, 2021, Sex Differences in Nonalcoholic Fatty Liver Disease: Estrogen Influence on the Liver–Adipose Tissue Crosstalk. Antioxidants & Redox Signaling, 35: 753–774.

Shaheen M, Schrode KM, Pan D, et al., 2021, Sex-Specific Differences in the Association Between Race/Ethnicity and NAFLD Among US Population. Frontiers in Medicine, 8: 795421.

Yang M, Liu Q, Huang T, et al., 2020, Dysfunction of Estrogen-Related Receptor Alpha-Dependent Hepatic VLDL Secretion Contributes to Sex Disparity in NAFLD/NASH Development. Theranostics, 10: 10874.

Koo SH, 2013, Nonalcoholic Fatty Liver Disease: Molecular Mechanisms for the Hepatic Steatosis. Clinical and Molecular Hepatology, 19: 210.

Sanyal AJ, Castera L, Wong VW-S, 2023, Noninvasive Assessment of Liver Fibrosis in NAFLD. Clinical Gastroenterology and Hepatology, 21: 2026–2039.

Han SK, Baik SK, Kim MY, 2022, Non-Alcoholic Fatty Liver Disease: Definition and Subtypes. Clinical and Molecular Hepatology, 29: S5.

Gjorgjieva M, Sobolewski C, Dolicka D, et al., 2019, miRNAs and NAFLD: From Pathophysiology to Therapy. Gut, 68: 2065–2079.

Szabo G, Csak T, 2016, Role of MicroRNAs in NAFLD/NASH. Digestive Diseases and Sciences, 61: 1314–1324.

Dongiovanni P, Meroni M, Longo M, et al., 2018, miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. International Journal of Molecular Sciences, 19: 3966.

Targher G, Corey KE, Byrne CD, et al., 2021, The Complex Link Between NAFLD and Type 2 Diabetes Mellitus—Mechanisms and Treatments. Nature Reviews Gastroenterology & Hepatology, 18: 599–612.

Ferguson D, Finck BN, 2021, Emerging Therapeutic Approaches for the Treatment of NAFLD and Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 17: 484–495.

Lattuada G, Ragogna F, Perseghin G, 2011, Why Does NAFLD Predict Type 2 Diabetes? Current Diabetes Reports, 11: 167–172.

Younossi ZM, Golabi P, de Avila L, et al., 2019, The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Hepatology, 71: 793–801.

Caussy C, Aubin A, Loomba R, 2021, The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports, 21: 1–13.

Kasper P, Martin A, Lang S, et al., 2021, NAFLD and Cardiovascular Diseases: A Clinical Review. Clinical Research in Cardiology, 110: 921–937.

Xi Y, Li H, 2020, Role of Farnesoid X Receptor in Hepatic Steatosis in Nonalcoholic Fatty Liver Disease. Biomedicine & Pharmacotherapy, 121: 109609.

Zhou S, You H, Qiu S, et al., 2022, A New Perspective on NAFLD: Focusing on the Crosstalk Between Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and Farnesoid X Receptor (FXR). Biomedicine & Pharmacotherapy, 154: 113577.

Jiang C, Xie C, Li F, et al., 2015, Intestinal Farnesoid X Receptor Signaling Promotes Nonalcoholic Fatty Liver Disease. The Journal of Clinical Investigation, 125: 386–402.

Choudhary NS, Duseja A, 2021, Genetic and Epigenetic Disease Modifiers: Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Liver Disease (ALD). Translational Gastroenterology and Hepatology, 6: 2.

Theys C, Lauwers D, Perez-Novo C, et al., 2022, PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs? Biomedicines, 10: 3041.

Mocciaro G, Allison M, Jenkins B, et al., 2023, Non-Alcoholic Fatty Liver Disease Is Characterised by a Reduced Polyunsaturated Fatty Acid Transport via Free Fatty Acids and High-Density Lipoproteins (HDL). Molecular Metabolism, 73: 101728.

Nie T, Wang X, Li A, et al., 2024, The Promotion of Fatty Acid β-Oxidation by Hesperidin via Activating SIRT1/PGC1α to Improve NAFLD Induced by a High-Fat Diet. Food & Function, 15: 372–386.

Li N, Li X, Ding Y, et al., 2023, SREBP Regulation of Lipid Metabolism in Liver Disease, and Therapeutic Strategies. Biomedicines, 11: 3280.

Barreby E, Chen P, Aouadi M, 2022, Macrophage Functional Diversity in NAFLD—More Than Inflammation. Nature Reviews Endocrinology, 18: 461–472.

Petrescu M, Vlaicu SI, Ciumărnean L, et al., 2022, Chronic Inflammation—A Link Between Nonalcoholic Fatty Liver Disease (NAFLD) and Dysfunctional Adipose Tissue. Medicina, 58: 641.

Huby T, Gautier EL, 2022, Immune Cell-Mediated Features of Non-Alcoholic Steatohepatitis. Nature Reviews Immunology, 22: 429–443.

Naiki-Ito A, Yeewa R, Xiaochen K, et al., 2024, Hexane Insoluble Fraction from Purple Rice Extract Improves Steatohepatitis and Fibrosis via Inhibition of NF-κB and JNK Signaling. Food & Function, 15: 8562–8571.

Song Q, Zhang X, 2022, The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines, 10: 524.

Kobayashi T, Iwaki M, Nakajima A, et al., 2022, Current Research on the Pathogenesis of NAFLD/NASH and the Gut–Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome. International Journal of Molecular Sciences, 23: 11689.

Chen S-n, Tan Y, Xiao X-c, et al., 2021, Deletion of TLR4 Attenuates Lipopolysaccharide-Induced Acute Liver Injury by Inhibiting Inflammation and Apoptosis. Acta Pharmacologica Sinica, 42: 1610–1619.

Wu Q, Chen Z, Ding Y, et al., 2022, Protective Effect of Traditional Chinese Medicine on Non-Alcoholic Fatty Liver Disease and Liver Cancer by Targeting Ferroptosis. Front Nutr, 9: 1033129.

Hu XY, Luo Y, Zu F, et al., 2025, Effects of Electroacupuncture at “Fenglong” (ST40) and “Zusanli” (ST36) on the SIRT1/FOXO1 Signaling Pathway in Non-Alcoholic Fatty Liver Disease Model Rats. Zhen Ci Yan Jiu, 50: 150–158.

Duan H, Song S, Li R, et al., 2024, Strategy for Treating MAFLD: Electroacupuncture Alleviates Hepatic Steatosis and Fibrosis by Enhancing AMPK Mediated Glycolipid Metabolism and Autophagy in T2DM Rats. Diabetol Metab Syndr, 16: 218.

Yang R, Jiang D, Xu H, et al., 2024, Network Pharmacology and Molecular Docking Integrated with Molecular Dynamics Simulations Investigate the Pharmacological Mechanism of Yinchenhao Decoction in the Treatment of Non-Alcoholic Fatty Liver Disease. Curr Comput Aided Drug Des, 2024: 721–737.

Ren X, Chen H, Wang H, et al., 2024, Advances in the Pharmacological Effects and Mechanisms of Nelumbo Nucifera Gaertn. Extract Nuciferine. J Ethnopharmacol, 331: 118262.

Sahu B, Sahu M, Sahu M, et al., 2024, An Updated Review on Nelumbo Nucifera Gaertn: Chemical Composition, Nutritional Value and Pharmacological Activities. Chem Biodivers, 21: e202301493.

He Y, Tao Y, Qiu L, et al., 2022, Lotus (Nelumbo nucifera Gaertn.) Leaf-Fermentation Supernatant Inhibits Adipogenesis in 3T3-L1 Preadipocytes and Suppresses Obesity in High-Fat Diet-Induced Obese Rats. Nutrients, 14(20): 4348.

Nguyen ST, Nguyen HTT, Nguyen DCT, et al., 2025, Advancing UPLC-MS/MS for Mapping the Chemical Fingerprint of Bioactive Compounds in Lotus Leaves (Folium nelumbinis). J Pharm Biomed Anal, 261: 116840.

Yanan Z, Lu M, Lu Z, et al., 2023, Effects and Action Mechanisms of Lotus Leaf (Nelumbo nucifera) Ethanol Extract on Gut Microbes and Obesity in High-Fat Diet-Fed Rats. Front Nutr, 10: 1169843.

Kim AR, Jeong SM, Kang MJ, et al., 2013, Lotus Leaf Alleviates Hyperglycemia and Dyslipidemia in Animal Model of Diabetes Mellitus. Nutr Res Pract, 7: 166–171.

Liu QQ, Mi J, Du YY, et al., 2024, Lotusine Ameliorates Propionic Acid-Induced Autism Spectrum Disorder-Like Behavior in Mice by Activating D1 Dopamine Receptor in Medial Prefrontal Cortex. Phytother Res, 38: 1089–1103.

He S, Wang C, Shi W, et al., 2025, Assessment of the Properties and Mechanism of Three Lotus (Nelumbo nucifera Gaertn.) Parts for Sleep Improvement. Chem Biodivers, 22: e202402788.

Zhang Y, Wei Q, Luo Q, et al., 2025, XSBR-Mediated Biomass Polymers: A New Strategy to Solve the Low Toughness and High Hydrophilicity of Sodium Alginate Based Films and Use in Food Packaging. Int J Biol Macromol, 318: 144979.

Liu X, Guan B, Hu Z, et al., 2025, Combined Traditional Chinese Medicine and Probiotics (TCMP) Alleviates Lipid Accumulation and Improves Metabolism in High-Fat Diet Mice via the Microbiota-Gut-Liver Axis. Food Res Int, 207: 116064.

Liu J, Yan P, Li Y, et al., 2024, Gut Microbiota and Serum Metabolome Reveal the Mechanism by Which TCM Polysaccharides Alleviate Salpingitis in Laying Hens Challenged by Bacteria. Poult Sci, 103: 103288.

Su Y, Huang J, Shi P, et al. 2024, Lotus Leaf Extract Alleviates Lipopolysaccharide-Induced Intestinal Injury in Mice by Regulating Oxidative Stress and Inflammation. J Med Food, 27: 428–436.